SCRIPT: Trajectories and Mechanisms of Recovery From Malaria: An Observational Study

Sponsor
Imperial College London (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05149157
Collaborator
(none)
240
44.2

Study Details

Study Description

Brief Summary

This observational research study aims to answer the question: 'Which aspects of human biology play an important role in recovery from symptomatic malaria?'

In particular, the researchers aim to identify human genes for which the level of gene activity reflects the patient's overall rate of recovery. The researchers believe this approach may reveal new targets for adjunctive therapies.

The researchers aim to recruit 240 people, of all ages, who have been diagnosed with symptomatic malaria at selected hospitals in London. Blood samples, urine samples, and clinical information will be collected over the 14 days following malaria diagnosis.

Condition or Disease Intervention/Treatment Phase
  • Other: Symptomatic malaria

Study Design

Study Type:
Observational
Anticipated Enrollment :
240 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Search for Correlates of Recovery in the Patient Transcriptome (SCRIPT) (Malaria) Study
Anticipated Study Start Date :
May 2, 2022
Anticipated Primary Completion Date :
Jan 5, 2026
Anticipated Study Completion Date :
Jan 5, 2026

Outcome Measures

Primary Outcome Measures

  1. Genes for which expression (level of gene activity) correlates with a 'composite recovery score' [Each study participant will be assessed over the 14 days following malaria diagnosis]

    The 'composite recovery score' will be calculated by principal component analysis of rates of recovery for individual markers of tissue, organ, or organ system dysfunction, and extraction of the value of the first principal component for each participant. Genes for which expression correlates with the 'composite recovery score' will be identified by whole blood transcriptome analysis.

Secondary Outcome Measures

  1. Genes for which expression (level of gene activity) correlates with rate of recovery for individual markers of tissue, organ, or organ system dysfunction [Each study participant will be assessed over the 14 days following malaria diagnosis]

    Genes for which expression correlates with the individual markers of tissue, organ, or organ system dysfunction will be identified by whole blood transcriptome analysis.

  2. Rate of recovery for individual markers of tissue, organ, or organ system dysfunction [Each study participant will be assessed over the 14 days following malaria diagnosis]

    Rates of recovery will be calculated for individual markers of tissue, organ, or organ system dysfunction

  3. Sequences of clinical events predictive of recovery, as determined by Bayesian inference of dynamic pathways using the HyperTraPS statistical platform [Each study participant will be assessed over the 14 days following malaria diagnosis]

    Hypercubic transition path sampling (HyperTraPS) will be used to characterise patterns of recovery and identify predictors of fast vs slow recovery

Eligibility Criteria

Criteria

Ages Eligible for Study:
8 Days and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

Patients of any age with symptomatic malaria confirmed by asexual stage parasitaemia (of any Plasmodium species) on blood film.

Exclusion Criteria:

Patients with asymptomatic malaria; Patients with congenital malaria; Patients with Plasmodium gametocytaemia only; Patients with known HIV; Patients who have received antimalarial treatment for symptomatic malaria in the 28 days prior to hospital presentation; Patients who explicitly deny consent.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Imperial College London

Investigators

  • Principal Investigator: Aubrey Cunnington, PhD, Imperial College London

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Imperial College London
ClinicalTrials.gov Identifier:
NCT05149157
Other Study ID Numbers:
  • 21SM7226
First Posted:
Dec 8, 2021
Last Update Posted:
Mar 31, 2022
Last Verified:
Mar 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Imperial College London
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 31, 2022